本帖最后由 老马 于 2012-1-13 21:20 编辑
% p' G0 ]4 f' H p' ~& B, S, D0 }; O3 W- |/ k0 c7 x) c# S
爱必妥和阿瓦斯丁的比较6 D2 ?2 p( r' a1 q" K" |
+ f* ]% t! r r0 w8 Xhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/" a3 y% \( }, Z1 B; r: s
7 j' c1 Q! P- D- F8 I+ K9 b' L
3 X6 c: M, N: u1 y- S1 V, R, ~0 xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' y; `$ c% j! [2 [7 E7 u
==================================================: B+ U3 l5 `+ P2 N
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
1 y i; _ g F' CPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.; [; n) {1 K+ J9 ]9 Q' g7 n6 }% Y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( s5 t( _+ }3 D, I% x2 X8 z
|